QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

22,063 signal articles · 435 in last 24h · 106,488 total before filter · latest 40m ago
435last 24h
2472last 7d
480● bullish (7d)
254● bearish (7d)
200publishers
AllMacro188Earnings1528M&A128Regulatory15Product8Analyst24
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
New Chairman, Same Result: Fed Keeps Rates Steady Again
Barrons.com50d agoneutral
New Chairman, Same Result: Fed Keeps Rates Steady Again

In Kevin Warsh’s first vote as Fed chairman, the committee voted to keep interest rates unchanged on Wednesday. The decision, which was widely expected, comes as officials seek to determine if the recent oil shock will deliver long-term consequences to the broader economy. At the conclusion of a two-day policy meeting, the Federal Open Market Committee voted to keep its target for the federal-funds rate at 3.5% to 3.75% for the fourth consecutive meeting.

Big Bank Stocks Hit Records Ahead of Fed Meeting
Barrons.com50d agoneutral
Big Bank Stocks Hit Records Ahead of Fed Meeting

Shares of large U.S. banks outperformed the market on Wednesday, with some hitting records, as investors awaited the first Federal Open Market Committee meeting of Kevin Warsh’s Fed chairmanship. Investment banks Goldman Sachs and Morgan Stanley also rallied and hit records, according to FactSet and Dow Jones Market Data. Traders widely expect the Fed will keep the benchmark federal-funds rate target unchanged at a range of 3.50% to 3.75%.

Bank of America takes firm position on inflation, economy
TheStreet50d agoneutral
Bank of America takes firm position on inflation, economy

Every month, Bank of America surveys some of the world's largest institutional investors to build a picture of how professional money managers see the global economy. The latest edition of that survey landed with a specific number that stood out: Equity allocations had jumped to 50% overweight from ...

FedEx slowly recovers from operational meltdown in Vietnam
FreightWaves51d agoneutral
FedEx slowly recovers from operational meltdown in Vietnam

FedEx says it has significantly reduced cargo backlogs at its warehouses in Vietnam after a messy switch to a new ground delivery partner and new technology system. The post FedEx slowly recovers from operational meltdown in Vietnam appeared first on FreightWaves.

US stocks open higher, spotlight on Fed
Reuters51d agoneutral
US stocks open higher, spotlight on Fed

June 17 (Reuters) - The main U.S. stock indexes opened higher on Wednesday, as chip stocks rebounded ahead of the first interest rate decision under new Federal Reserve Chair Kevin Warsh.

Treasury Yields Rise Ahead of First Fed Decision Under Warsh
Barrons.com51d agoneutral
Treasury Yields Rise Ahead of First Fed Decision Under Warsh

Treasury yields tick higher ahead of the first interest rate decision under Fed Chairman Kevin Warsh. Rates are expected to remain unchanged. Investors are curious about how Warsh will change the central bank's communications with the public and its forward guidance.

Micron Stock Rebounds But Memory-Chip Frenzy Faces a Fed Test
Barrons.com51d agoneutral
Micron Stock Rebounds But Memory-Chip Frenzy Faces a Fed Test

Micron Technology stock was back on the rise early Wednesday as the memory-chip maker looks to resume its relentless rally. Micron was leading the rebound in premarket trading, rising 3.5%, the second-best performer in the Only Intel was climbing more ahead of the open. When there’s nothing happening Micron stock tends to gain.

Big pharma taps UK playbook to pressure Europe on drug prices
Reuters Videos51d agoneutralVIDEO
Big pharma taps UK playbook to pressure Europe on drug prices

<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing.&nbsp;</p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers.&nbsp;</p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs.&nbsp;</p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines.&nbsp;</p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up.&nbsp;</p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation.&nbsp;</p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to ​lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>

WeRide and Uber Target Zurich Robotaxi Launch as European Expansion Accelerates
InvestorsHub51d agoneutral
WeRide and Uber Target Zurich Robotaxi Launch as European Expansion Accelerates

WeRide (NASDAQ:WRD) and Uber Technologies (NYSE:UBER) plan to introduce commercial robotaxi services in the Greater Zurich Region later this year, extending their autonomous mobility partnership in Europe following a recent deployment announcement in Madrid. The service is expected to launch during 2026, pending approval from Switzerland’s Federal Roads Office (FEDRO).